Browse by author
Lookup NU author(s): Dr Philip Hampton
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2023, The Author(s). Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Author(s): Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG
Publication type: Article
Publication status: Published
Journal: Drugs
Year: 2023
Volume: 83
Pages: 1255-1267
Online publication date: 23/08/2023
Acceptance date: 01/08/2023
Date deposited: 13/09/2023
ISSN (print): 0012-6667
ISSN (electronic): 1179-1950
Publisher: Springer
URL: https://doi.org/10.1007/s40265-023-01931-3
DOI: 10.1007/s40265-023-01931-3
Data Access Statement: Not applicable.
PubMed id: 37610614
Altmetrics provided by Altmetric
